Short answer
Amylyx Pharmaceuticals, Inc. (AMLX) filed an 8-K current report with the SEC on November 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q3 2026 financial results for quarter ended September 30, 2026.
Amylyx Pharmaceuticals, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q3 2026 financial results for quarter ended September 30, 2026
- Press release issued November 5, 2026
- Detailed results available in Exhibit 99.1
Item EX-99.1 · Exhibit EX-99.1
- Phase 3 LUCIDITY met its primary endpoint, reducing Level 2 and 3 hypoglycemic events 55% versus placebo, with p=0.000003
- Avexitide NDA submission remains targeted for end-2026, supporting a potential 2027 launch if FDA-approved
- Public offering generated approximately $544.6 million, lifting cash, equivalents and securities to $768.1 million
- Third-quarter net loss widened to $45.5 million, or $0.38 per share, from $34.4 million, or $0.37 per share
- R&D expense rose to $28.4 million and SG&A to $21.3 million, reflecting trial spending and commercial launch preparation
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Amylyx Pharmaceuticals, Inc. 8-K filings
Get the next AMLX 8-K as it lands
Follow AMLX for push alerts, or ask the research agent what this filing means.